

Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Not yet assigned 10/072,419
		Filing Date	Filed herewith
		First Named Inventor	Bernice Schacter
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 1 of 3	Attorney Docket Number	10739-1	

10/072419
02/07/02

U.S. PATENT DOCUMENTS				
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY
JR	4,260,601		Reichelt <i>et al.</i>	04/1981
JR	4,328,134		Schally <i>et al.</i>	05/1982
JR	4,489,059		Rossini <i>et al.</i>	12/1984
JR	4,464,356		Mordes <i>et al.</i>	08/1984
JR	4,891,219		Karr, Jr. <i>et al.</i>	01/1990
JR	5,219,579		Tisdale <i>et al.</i>	06/1993
JR	5,385,740		Tisdale <i>et al.</i>	01/1995
JR	5,830,994		D'Hinterland <i>et al.</i>	11/1998

class/subcl.

514/18
525/54.11
424/573
424/573
424/195.1
424/573
424/573
530/300

FOREIGN PATENT DOCUMENTS					
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.			
JR	GENBANK ® Database, Accession No. 7246026, (February 2, 1999)			
JR	GENBANK ® Database, Accession No. P25311, (August 20, 2001)			
JR	GENBANK ® Database, Accession No. XP_028425 (August 27, 2001)			
JR	GENBANK ® Database, Accession No. XP_028426 (August 27, 2001)			
JR	BECK, <i>et al.</i> , Lipid mobilizing factors specifically associated with cancer cachexia, Br. J. Cancer, 63(6):846-850 (1991) (abstract only)			
JR	BECK, <i>et al.</i> , Lipolytic factors associated with murine and human cancer cachexia, J. Natl. Cancer Inst., 82(24):1922-1926 (1990) (abstract only)			
JR	FRUEBIS <i>et al.</i> , Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice, PNAS, Vol. 98, No. 4, pp. 2005-2010 (2001)			
JR	GADE, Hyperproliferation caused by novel members of the adipokinetic hormone/red pigment-concentrating hormone family of peptides isolated from corpora cardiaca of onitine beetles, Biochem. J. 321:201-206 (1997)			
JR	GADE, <i>et al.</i> , Structure - Activity Relationships for <i>Periplaneta americana</i> Hypertrehalosemic Hormone I: The Importance of Side Chains and Termini, Peptides, Vol. 16, No. 7, pp. 1173-1180 (1995)			
JR	GOLDSWORTHY, <i>et al.</i> , Structures, Assays and Receptors for Locust Adipokinetic Hormones, Comp. Biochem. Physiol., Vol. 117B, No. 4, pp. 483-496 (1997)			
JR	HAYES, <i>et al.</i> , Insect Hypertrehalosemic Hormone: Isolation and Primary Structure from <i>Blaberus discoidalis</i> Cockroaches, Biochemical and Biophysical Research Communications, Vol. 140, No. 2, pp. 674-678 (1986)			
JR	HIRAI, <i>et al.</i> , Biological Evaluation of a Lipid-mobilizing Factor Isolated from the Urine of Cancer Patients, Cancer Research 58, 2359-2365 (1998)			
JR	HOLLANDER, <i>et al.</i> , Demonstration of lipolytic activity from cultured human melanoma cells, J. Surg. Res., 40(5): 445-449 (1986)			
JR	INUI, Cancer Anorexia-Cachexia Syndrome, Cancer Research 59(18):4493-4501 (1999)			

Jeffrey E. Russell

October 7, 2003

Examiner Signature			Date Considered	
Form PTO/SB/08B		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Not yet assigned - 10/072,419	
		Filing Date	Herewith	
		First Named Inventor	Not yet assigned	
		Group Art Unit	Not yet assigned	
		Examiner Name	Not yet assigned	
Sheet 2 of 3	Attorney Docket Number		10739-1	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.		T ₁
JR	KENNEDY, <i>et al.</i> , Hydrophobic Ligand Binding by Zn- α_2 -glycoprotein, a Soluble Fat-depleting Factor Related to Major Histocompatibility Complex Proteins, J. Biol. Chem. Vol. 276, Issue 37, pp. 35008-35013 (2001) (abstract only)		
JR	KHAN, <i>et al.</i> , Catabolism of adipose tissue by a tumor-produced lipid mobilizing factor, Int. J. Cancer, 80(3):444-447 (1999) (abstract only)		
JR	KITADA, <i>et al.</i> , Characterization of a lipid mobilizing factor from tumors, Prog. Lipid Res. 20:823-6 (1981) (abstract only)		
JR	KITADA, <i>et al.</i> , Lipolysis induction in adipocytes by a protein from tumor cells, J. Cell Biochem., 20(4):409-16 (1982) (abstract only)		
JR	KNUDTZON, <i>et al.</i> , Acute in vivo stimulatory effects of human pituitary lipid-mobilizing factor on plasma levels of glucagon and insulin in rabbits, Horm. Metab. Res., 1:1-6 (1984) (abstract only)		
JR	KÖLLISCH, <i>et al.</i> , Structure elucidation and biological activity of an unusual adipokinetic hormone from corpora cardiaca of the butterfly, <i>Vanessa cardui</i> , Eur. J. Biochem. 267:5502-5508 (2000)		
JR	LEWIS, <i>et al.</i> , Hypertrehalosemic hormone in a cockroach: molecular cloning and expression, Molecular and Cellular Endocrinology, 130:101-108 (1997)		
JR	LORENZ, <i>et al.</i> , Hypertrehalosemic peptides in the honeybee (<i>Apis mellifera</i>): purification, identification, and function, J. Insect Phy. 45:647-653 (1999)		
JR	McDEVITT, <i>et al.</i> , Purification and Characterization of a Lipid-mobilizing Factor Associated with Cachexia-inducing Tumors in Mice and Humans, Cancer Research, 55:1458-1463 (1995)		
JR	OSUGA, <i>et al.</i> , Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity, PNAS, Vol 97, Issue 2, pp. 787-792 (2000)		
JR	PRICE, <i>et al.</i> , Mechanism of inhibition of a tumor lipid-mobilization factor by eicosapentaenoic acid, Cancer Research, Vol. 58, Issue 21, 4827-4831 (1998)		
JR	RAINA, <i>et al.</i> , Primary Structure of a Novel Neuropeptide Isolated from the Corpora Cardiaca of Periodical Cicadas Having Adipokinetic and Hypertrehalosemic Activities, Insect Biochem Mol. Biol., Vol 25, No. 8, pp. 929-932 (1995)		
JR	RICHTER, <i>et al.</i> , Peptide hormones and lipolysis in rabbit adipocytes, Horm. Metab. Res., 17(3):127-30 (1985) (abstract only)		
JR	RICHTER, <i>et al.</i> , Lipolytic potency of proopiomelanocorticotropin peptides in vitro, Neuropeptides, 9(1):59-74 (1987) (abstract only)		
JR	RICHTER, <i>et al.</i> , On the in vitro lipolytic activity of peptide hormones in human adipose tissue, Horm. Metab. Res. Suppl., 19:44-49 (1998) (abstract only)		
JR	ROEDER, Octopamine in Invertebrates, Progress in Neurobiology, Vol 59, pp. 533-561 (1999)		
JR	SALTIEL, Another hormone-sensitive triglyceride lipase in fat cells?, PNAS, Vol. 97, Issue 2, pp. 535-537 (2000)		
JR	SANCHEZ, <i>et al.</i> , Crystal Structure of Human ZAG, a Fat-Depleting Factor Related to MHC Molecules, Science, Vol. 283, pp. 1914-1919 (1999)		
JR	SASEK, <i>et al.</i> , An antiserum to locust adipokinetic hormone reveals a novel peptidergic system in the rat central nervous system, Brain Research, 343:172-175 (1985)		
JR	SCHUELER, <i>et al.</i> , Identification and Initial Characterization of Adipokinetic Hormone-Like Immunoreactive Peptides of Rat Origin, Journal of Neurochemistry, pp. 133-138 (1986)		

Examiner Signature	Jeffrey E. Russell	Date Considered	October 7, 2003
--------------------	--------------------	-----------------	-----------------



PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/072,419
		Filing Date	7 February 2002
		First Named Inventor	Bernice Schacter
		Art Unit	1654
		Examiner Name	Jeffrey E. Russel
Sheet 1	of 1	Attorney Docket Number	E0542-00001

RECEIVED

JUN 09 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JR		Jaffe et al., 1986, Biochem. Biophys. Res. Commun. 135 (2) 622-628 (abstract only)	
JR		Jaffe et al., 1988, Biochem. Biophys. Res. Commun. 155 (1) 344-350 (abstract only)	
JR		Jaffe et al., 1989, Proc. Natl. Acad. Sci. USA 86: (20): 8161-8164 (abstract only)	

Examiner Signature	Jeffrey E. Russel	Date Considered	October 7, 2003
--------------------	-------------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.